Search

Your search keyword '"Holash, Jocelyn"' showing total 171 results

Search Constraints

Start Over You searched for: Author "Holash, Jocelyn" Remove constraint Author: "Holash, Jocelyn"
171 results on '"Holash, Jocelyn"'

Search Results

5. VEGF-Trap: A VEGF Blocker with Potent Antitumor Effects

8. Supplemental Figures 1-5 from A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function

12. Supplementary Figures S1-S6 from Sustained VEGF Blockade Results in Microenvironmental Sequestration of VEGF by Tumors and Persistent VEGF Receptor-2 Activation

14. Supplemental Figure legends from A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function

20. Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

21. Supplemental Figures and Table from Preclinical Antitumor Activity of a Novel Anti–c-KIT Antibody–Drug Conjugate against Mutant and Wild-type c-KIT–Positive Solid Tumors

27. Vascular-specific growth factors and blood vessel formation

28. Angiopoietin-1 protects the adult vasculature against plasma leakage

29. Essential role for oncogenic Ras in tumour maintenance

30. Contributors

32. Reciprocal expression of the Eph receptor Cek5 and its ligand(s) in the early retina

34. Polarized expression of the receptor protein tyrosine kinase Cek5 in the developing avian visual system

35. Preclinical Antitumor Activity of a Novel Anti–c-KIT Antibody–Drug Conjugate against Mutant and Wild-type c-KIT–Positive Solid Tumors

37. Ephrin-B2 Selectively Marks Arterial Vessels and Neovascularization Sites in the Adult, with Expression in Both Endothelial and Smooth-Muscle Cells

38. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies

39. A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function

40. The identification and characterization of a STAT5 gene signature in hematologic malignancies

41. Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

43. Abstract A140: Evaluation of prediction of in vivo activity from in vitro combinations: Examples using a MEK1/2 inhibitor combined with docetaxel in NSCLC models.

44. Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors

46. Identification of pSTAT5 gene signature in hematologic malignancy.

47. Abstract 2058: Systematic evaluation of drug combinations in vitro and in vivo.

49. Abstract DDT02-02: Preclinical development of LFA102, a highly potent and selective neutralizing antibody against the prolactin receptor

Catalog

Books, media, physical & digital resources